Eli Lilly Applies For Additional Indication For Gemzar For Relapsed Or Refractory Malignant Lymphoma
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan announced Sept. 10 it has applied for an additional indication for Gemzar (gemcitabine) for “relapsed or refractory malignant lymphoma”.